The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
FDA approves treosulfan plus fludarabine as an allo-HSCT preparative regimen in patients with AML or MDS
On January 22, 2025, the U.S. Food and Drug Administration (FDA) granted approval to treosulfan, an alkylating agent, in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients aged >1 year with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).1
The approval was based on findings from the randomized, active-controlled, MC-FludT.14/L trial II (NCT00822393) of treosulfan vs busulfan as a preparative regimen for allo-HSCT in combination with fludarabine.1 A total of 570 patients randomized to treosulfan (n = 280) or busulfan (n = 290) were included.1
- Treatment with treosulfan provided survival benefits over busulfan with hazard ratios for OS (stratified by donor type and risk group) of 0.73 (95% confidence interval [CI], 0.51–1.06) in patients with AML and 0.64 (95% CI, 0.40–1.02) in patients with MDS.1
- The most common adverse reactions occurring in ≥20% of patients were musculoskeletal pain, stomatitis, pyrexia, nausea, edema, infection, and vomiting. Selected Grade 3/4 nonhematologic laboratory abnormalities were elevated levels of gamma-glutamyl transferase, bilirubin, alanine aminotransferase, aspartate aminotransferase, and creatinine.1
The recommended dose of treosulfan is 10 g/m2 once daily on Days −4, −3, and −2, alongside fludarabine 30 mg/m2 once daily on Days −6, −5, −4, −3, and −2 of allo-HSCT infusion on Day 0.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
